Is pulmonary embolism really all that bad?… Again…

CTPA PE

Pollack, Charles V, Donald Schreiber, Samuel Z Goldhaber, David Slattery, John Fanikos, Brian J O’Neil, James R Thompson, et al. “Clinical Characteristics, Management, and Outcomes of Patients Diagnosed with Acute Pulmonary Embolism in the Emergency Department: Initial Report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry)..” Journal of the American College of Cardiology 57, no. 6: 700–706. doi:10.1016/j.jacc.2010.05.071. PMID 21292129

METHODS

  • this was a large ED based registry study from multiple US EDs to see how PE patients present and what happened to them
  • it included both people who ended up having a confirmed PE and those empirically treated for PE awaiting tests and ultimately ruled out for PE
  • PE diagnosis could be based on lots of different tests (all appropriate I think)

RESULTS

  • 2400 pts, 1800 who had PE
  • vast majority (90%) diagnosed by CT
  • 3% were hypotensive on presentation
  • SOB, pain, and symptoms suggesting DVT were commonest presenting complaints
  • 5% presented with syncope: it happens but it’s not common
  • of those who got echoes (only a quarter) there was RV dyskinesia in half
  • 85% of those with PE got anti-coagulated in the ED – this is lower than I expected, though presumably because they had contra-indications.
  • mortality rate attributable to PE was 1.1% (though all cause mortality was 5.4% meaning that lots of sick people get PEs and die of something else)

COMMENTARY

I know I’ve ranted on this before but I do find it fascinating.

I grew up with the notion that PE killed roughly 1 in 5 of those with the disease. That’s kind of scary. That’s similar to STEMI mortality. There is no doubt that there was a time when the PEs we diagnosed carried that type of mortality. Big feck-off PEs that is.

As the technology has changed we have created a new disease – let’s call them pulmonary fluff instead of pulmonary emboli. Emboli are terrifying, fluff not so much.

We have presumed that pulmonary fluff is the same disease as the big bad pulmonary emboli.

We are left with, i think, with two possible conclusions

  1. we seem to have discovered a treatment (in heparin) that reduces mortality from 20% to 1%. An absolute risk reduction (ARR) of 19%. Considering that lytics for STEMI probably by you a 2% ARR we should be absolutely stunned.
  2. The alternative is that we are now diagnosing lots of pulmonary fluff and the mortality rate from pulmonary fluff is 1% at a baseline and giving all this people heparin to treat their fluff does nothing; an ARR of 0%.

It may be somewhere in between those 2 answers but we have yet to make up our mind which.

 

Should we anti-coagulating all those patients in plaster casts?

Click for source

Interesting enough question. We know having a big cast on is a risk factor for VTE. I’ve seen one young guy die from a massive PE with a big cast on his leg.

It mightn’t be common, it mightn’t justify risk and expense but it’s definitely a valid question. But do we have an answer as yet?

I figured this paper might help me answer it.

Meek, Robert, and Roger Lien-Kien Tong. “Venous Thromboembolism in Emergency Department Patients with Rigid Immobilization for Lower Leg Injury: Incidence and Risk Factors..” Emergency Medicine Australasia : EMA 24, no. 3: 277–284. PMID 22672168

 

INTRO

  • Australia madated that all lower limb casts get LMWH. The guideline was for in patients (from what I can make out) but are ED patients really different.

METHODS

  • chart review using various search terms to pull out all the patients with lower limb casts
  • tried to ascertain from records if they developed a VTE (obviously this can be a little problematic)
  • they also tried to contact everyone in a 3 month period by post and phone to see if they ‘d had a VTE (also a little problematic)

RESULTS

  • initial search yielded 10000, they narrowed this down to 6800 >18 and reviewing records left 1200 who actually got a splint
  • found 33 VTEs (2.7%)
  • in the small 3 month cohort (180 pts) who they actually contacted the rate was 1.7% (or 3 pts…)
  • when they put together the VTE they found on chart review and those they found on postal survey they come up with a number between 3 and 7% incidence.

So after reading that, i’m not sure I really have my question answered. Is there anywhere else I can turn to?

Serendipitously there has just been a Best Bet published on this very topic. They come to the conclusion that the rate is about 11%.

More importantly the bet itself is in part put together by thegreatnortherno who is our great shining hope and is going to tell us all what should be doing. At least that’s what EMManchester says.

As is only fitting StEmlyns have a whole post on it so go read that.

Are small PEs more benign? Probably but this doesn’t help.

Cha S-I, Shin K-M, Lee J-W, Lee J, Lee S-Y, Kim C-H, et al. Clinical characteristics of patients with peripheral pulmonary embolism. Respiration. 2010;80(6):500–508. PMID 20110642

Someone alerted me to this paper and I’m not sure who. If it was you let me know and I can at least give you credit!

Of course, this is a really important question – do the small PEs do OK without anticoagulation? I’m not sure this helps much.

METHODS

  • unfortunately terrible
  • EMR chart review
  • pts included were those who had CTPA with the legs included
  • so we can’t be sure about the clinical features of actual PE pts cause we don’t know if they are all in the study
  • classifed radiologically after the fact as big or small
  • did things like try and calculate a Well’s score retrospectively (how can you decide if P an alternate diagnosis is likely from a chart? – with difficulty…)

RESULTS

  • 250 pts: most big, very few sub-segmental so that limits the results of the group that we’re actually interested in
  • 60% of the smaller PEs were defined as incidental (though I don’t really know what his means. Were the scans for some other acute pathology or routine follow up for cancer etc…?)
  • the big ones got treated, the smaller ones often didn’t. Again, I don’t know what this means

THOUGHTS

  • they suggest that sub-segmentals have a more benign outcome and that’s likely true, but this is no proof of it.

Does giving heparin early improve mortality in PE?: Three Answers in increasing detail

[I suspect every emergency medicine blog eventually gets caught in the overwhelming gravitational pull of the VTE literature till it collapses into itself and sucks the whole of the internet into a wormhole. Apparently CERN is actually colliding the URLs of the EM blogosphere into one another to find the Higg's boson. Or something like that...]


Smith, S B et al 2010. “Early Anticoagulation Is Associated With Reduced Mortality for Acute Pulmonary Embolism.” Chest 137 (6) (June 3): 1382–1390. doi:10.1378/chest.09-0959. PMID 20081101

Answer One – So you can get back to your life

Maybe? How the hell should I know?…

Answer Two – The slightly wordy hyperbolic rejection of the study’s conclusions

The above study shows compellingly that the administration of heparin the ED predicts pts with PE who are less sick

Answer Three – The, hopefully more nuanced and reasoned discussion…

Hat tip to Dr Weingart for alerting me to this paper

METHODS

  • their question was whether timing of heparinisation was linked to mortality in PE pts
  • chart review – dubious methods

OK, os that requires some qualification. You’ll recognise that’s Hoffman phrase. I’ll explain.

A chart review means that someone sits down with a chart they’re interested in and write down the bits that are relevant to the research question. No worries so far.

The problem is that when the doctor was writing the chart initially, they didn’t know someone would be sitting down with the chart later to try and answer a research question. As a result, lots of the time the information that the researcher is looking for isn’t there.

Even if it is there it’s hard to know what it means. The biggest problem comes here with subjective findings like symptoms, or the even more complex decision making process that goes on in a docs brain. These things aren’t always that clearly documented.

For that reason you need to be careful how you do it. There are recommended methods.

These guys didn’t do much of that. They didn’t tell us what they did about missing data (but it becomes clear there was a fair bit of it). They don’t get two people to look at the same chart and see if they agree.

Perhaps one of the most problematic issues is their calculation of a Well’s score. The gestalt/alternative diagnosis part is of course (as it should be) subjective and is going to be tremendously difficult to abstract from a chart unless they write out a Well’s score. Maybe they did this. They don’t tell us.

RESULTS

  • 400 pts from a 3 yr period
  • they say:

392 patients (98.0%) were accounted for by 30 days

I’m not sure what that means. Presumably that means they attended a follow up clinic. Or maybe it means they weren’t recorded as dead on the hospital system at 30 days. Again, they don’t tell us.

  • 3% dead in hospital, 7.7% dead by 30 days
  • pts who received heparin in the ED had a lower in-hospital mortality (1.4% vs 6.7%)

At this point a moment in honour of XKCD

People who get thrombolytics are more likely to die than those who don’t. Either thrombolytics are killing people OR people who get thrombolytics are having strokes and heart attacks and those who don’t are healthy.

Effectively that’s all that the statement “pts who received heparin in the ED had a lower in-hospital mortality (1.4% vs 6.7%)” can tell us. Either heparin given early is great OR people who got heparin earlier were less sick.

  • the benefit for early heparin was maintained even after adjustment for co-morbidities

They say:

To account for comorbidities that would confound the relationship between the timing of anticoagulation and mortality, we calculated propensity scores and did subgroup analyses

Admission – I haven’t a clue how to calculate a propensity analysis. I am a half-(ass)-trained emergency doc who reads a lot. I’m still a bit dubious that you can account for significant differences between groups by statistics. This depends on knowing what the differences are. In the words of Donald Rumsfeld (Oh Lord, I’m actually quoting Donald Rumsfeld…)

There are known knowns, known unknowns, and unknown unknowns…

Propensity analysis can only account for the differences we know between the groups concerned. Correct me if I’m wrong on that – and it’ll not be the first time…

To give the authors credit they acknowledge this in the discussion:

Nevertheless, this was a retrospective study that did not have the advantage of randomization of patients to early vs late anticoagulation. Therefore, even with propensity score modeling, we can only demonstrate associations rather than prove cause and effect.

So why the difference in the two groups?

the folk who got treated later with heparin seemed to be more difficult to diagnose. It seems people admitted them thinking they were flares of COPD or MIs when actually they were PEs. They also seemed to be sicker overall (age being the main difference).

PE is a bugger of a disease to diagnose, and even to work out what a diagnosis means. Heparin may well help in PE, in fact I’m pretty sure it does for some people at the very least. And it may well help to give it early, at least in terms of hours or days as opposed to minutes (like tPA in MI). I’m just not sure this gives us the answer.

The most important learning point I would take home from this paper is that we miss PE on a frequent basis, especially, it seems in people with COPD or MI where we think we have the diagnosis sealed prematurely.

On the other hand we probably overdiagnose it in other people but that’s another story…

“Time trends in pulmonary embolism in the United States: evidence of overdiagnosis..” Archives of internal medicine 171 (9) (May 9): 831–837

Wiener, Renda Soylemez, Lisa M Schwartz, and Steven Woloshin. 2011. “Time trends in pulmonary embolism in the United States: evidence of overdiagnosis..” Archives of internal medicine 171 (9) (May 9): 831–837. PMID 21555660

Found this via a chap who commented on Weingart’s now famous PE episode.

I think this paper raises a lot of good points surrounding the “epidemic” of overdiagnosis of PE. The VTE literature is vast and complex yet some of the most basic questions lack substantive evidence.

The evolution of our approach to VTE has dramatically altered what a diagnosis of VTE actually means.

This paper is one of the first I’ve seen that tries to examine whether or not it’s fair to say that we are overdiagnosing PE. It is of course indirect evidence. Direct evidence would be a comparative trial of treatment vs no treatment.

METHODS

  • they used the Nationwide Inpatient Sample to get the data. This is a huge dataset that is all ICD-9 codes from hospital discharges. ICD-9 codes have their problems but in this question they’re less relevant
  • they compared the number of diagnoses of PE with the recorded mortality from PE. If all the PEs being diagnosed were of equal lethality then finding more of them and treating them should result in a lower mortality rate
  • below is a graph of 3 potential outcomes

RESULTS

  • the numbers of patients involved are in the hundred of thousands
  • I think the little graph tells the story pretty well:

just like option 3 in the image above

  • there was a big increase in the number of PEs but no change in the mortality rate implying that we were just finding lots of PEs that don’t seem to kill people
  • they tease this out with a bit more stats in the paper if you’re interested